Table 4.

Hydroxyl radical-scavenging, quinone reductase-inducing, NF-κB inhibitory, and cytotoxic activities of compounds 1–11.

compound	hydroxy radical- scavenging	quinone reductase induction			NF-κB inhibition	cytotoxicity
	ED50a (μM)	CDb (μM)	IC50c (μM)	CId	IC50e (μM)	IC50f(μM)
1	0.71	7.4	9.2	1.3	0.006	1.6
2	0.73	3.0	10.8	3.6	1.5	4.5
3	0.94	2.1	15.6	7.4	0.44	4.2
4	2.6	13.3	41.3	3.1	0.06	>10
5	18.5	>20	>100	NAg	0.70	>10
6	>20	>20	>100	NAg	0.34	>10
7	>20	>20	>100	NAg	0.23	>10
8	2.2	13.0	>100	>7.7	0.45	>10
9	1.0	19.6	74.3	3.8	>20	>10
10	0.60	>20	>100	NAg	>20	>10
11	0.63	>20	>100	NAg	>20	>10
quercetinh	1.2
L-sulforaphanei		0.71	15.2	21.4
rocaglamidej					0.08
paclitaxelk						0.0006

^aED₅₀, concentration scavenging hydroxyl radical by 50%. Compounds with ED₅₀ values of <20 μ M are considered active.

^bCD, concentration required to double quinone reductase activity. Compounds with CD values of <20 μM are considered active.

^cIC₅₀, concentration inhibiting hepa1c1c7 cell growth by 50%.

^dCI, Chemoprevention Index (= IC₅₀/CD).

^eIC₅₀, concentration inhibiting NF-κB p65 by 50%. Compounds with IC₅₀ values of <20 μ M are considered active.

^fIC₅₀, concentration inhibiting HT-29 cell growth by 50%. Compounds with IC₅₀ values of <10 μ M are considered active.

^gNA, not applicable.

^hPositive control for hydroxyl radical-scavenging assay.

ⁱPositive control for quinone reductase induction assay.

^jPositive control for NF-κB p65 inhibition assay.

^kPositive control for cytotoxicity assay against HT-29 cell line.